ICM Asset Management’s Harvard Bioscience HBIO Stock Holding History

ICM Asset Management’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-1,625	Closed	-$61K	–	52
2017 Q3	$61K	Sell	1,625 -9,301	-85%	-$275K	0.07%	49
2017 Q2	$279K	Sell	10,926 -1,159	-10%	-$28.7K	0.35%	45
2017 Q1	$314K	Sell	12,085 -2,781	-19%	-$80.1K	0.4%	47
2016 Q4	$453K	Buy	+14,866	New	+$378K	0.64%	40

Other funds holding HBIO

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GPC

Glacier Peak Capital Bellevue, Washington $96.2M AUM 0.45% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

SBH

Segall Bryant & Hamill Chicago, Illinois $6.98B AUM 34.78% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

ICM Asset Management's HBIO Position: Q4 2017 in Review

ICM Asset Management sold out of Harvard Bioscience (HBIO) in Q4 2017, closing a stake of 1,625 shares — an estimated $61K sold.

ICM Asset Management first reported a position in HBIO in Q4 2016 and held it in 4 quarters. The position peaked at $453K in Q4 2016. 55 funds tracked by Wall St. Rank hold HBIO as of Q4 2017.

ICM Asset Management reported no remaining Harvard Bioscience position as of Q4 2017 after selling out during the quarter.
ICM Asset Management sold 1,625 Harvard Bioscience shares in Q4 2017, an estimated $61K.
ICM Asset Management first reported a position in Harvard Bioscience in Q4 2016 and held it in 4 quarters.
ICM Asset Management's Harvard Bioscience position peaked at $453K in Q4 2016.
55 funds tracked by Wall St. Rank held Harvard Bioscience as of Q4 2017.

Based on ICM Asset Management's 13F filing for Q4 2017, filed 15 Feb 2018.